+ Watch GERN
on My Watchlist
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
Cancer vaccines based on telomerase reverse transcriptase (TERT), which repairs damaged telomeres. Telomeres are the caps at the end of chromosomes. These shorten every time a cell divides as a natural check and balance to cell division. Some cancer cells - the ones that become tumors - have the TERT enzyme and can repair these shortened telomeres. So, the proposed vaccine will include make TERT a target of the body's immune system, thus targeting runaway cancer cells. The science behind these drugs is worth the risk.
But won't that cause auto-immune disease and reduced longevity? Sounds like a bad plan to me.
TERT isn't produced by normal body cells, so cells that divide uncontrollably or produce too many errors during replication are themselves targeted by the immune system. Also, there are many ways to deliver APIs to an affected area. Think about IMGN or SGEN. They have Ph.Ds up the wazoo for a reason!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions